Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

37.38USD
16 Jul 2018
Change (% chg)

$-0.15 (-0.40%)
Prev Close
$37.53
Open
$37.50
Day's High
$37.54
Day's Low
$37.29
Volume
6,510,871
Avg. Vol
7,123,409
52-wk High
$39.43
52-wk Low
$32.33

Latest Key Developments (Source: Significant Developments)

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy
Monday, 16 Jul 2018 

July 16 (Reuters) - Pfizer Inc ::PFIZER INITIATES PIVOTAL PHASE 3 PROGRAM FOR INVESTIGATIONAL HEMOPHILIA B GENE THERAPY.  Full Article

FDA Approves XTANDI For Treating Men With Non-Metastatic Castration-Resistant Prostate Cancer
Saturday, 14 Jul 2018 

July 13 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) FOR THE TREATMENT OF MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) FOR THE TREATMENT OF MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).ASTELLAS PHARMA - U.S. FDA APPROVES XTANDI FOR TREATING MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BASED ON RESULTS FROM PHASE 3 PROSPER TRIAL.  Full Article

Pfizer To Organize Company Into Three Businesses
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Pfizer Inc ::PFIZER TO ORGANIZE FOR FUTURE GROWTH.PFIZER INC - WILL ORGANIZE COMPANY INTO THREE BUSINESSES.PFIZER INC - NEW HOSPITAL BUSINESS UNIT CREATED WITHIN INNOVATIVE MEDICINES.PFIZER INC - CHANGES WILL BE EFFECTIVE AT BEGINNING OF COMPANY'S 2019 FISCAL YEAR.PFIZER INC - CONSUMER HEALTHCARE (PCH) BUSINESS WILL INCLUDE ALL OF PFIZER'S OVER--COUNTER MEDICINES.PFIZER INC - CHANGES IN ORGANIZATIONAL STRUCTURE NOT EXPECTED TO IMPACT CURRENT CAPITAL ALLOCATION PRIORITIES OR FULL-YEAR 2018 FINANCIAL GUIDANCE.PFIZER INC - CONTINUES TO EVALUATE STRATEGIC ALTERNATIVES FOR PCH BUSINESS AND EXPECTS TO MAKE A DECISION IN 2018.PFIZER INC - WILL ORGANIZE CO INTO SCIENCE-BASED INNOVATIVE MEDICINES BUSINESS, OFF-PATENT BRANDED & GENERIC ESTABLISHED MEDICINES BUSINESS.PFIZER INC - WILL ALSO ORGANIZE CO INTO CONSUMER HEALTHCARE BUSINESS.PFIZER - EXPECTED REDUCTION IN IMPACT OF PATENT PROTECTION LOSSES POST-2020 AFTER EXCLUSIVITY LOSS OF LYRICA IN U.S EXPECTED TO OCCUR IN OR AFTER DEC.PFIZER INC - BASED ON 2017 ACTUAL RESULTS, INNOVATIVE MEDICINES BUSINESS IS EXPECTED TO COMPRISE APPROXIMATELY THREE-QUARTERS OF PFIZER'S REVENUES.PFIZER INC - BASED ON 2017 ACTUAL RESULTS, ESTABLISHED MEDICINES BUSINESS IS EXPECTED TO COMPRISE APPROXIMATELY ONE QUARTER OF REV.PFIZER INC - WHEN CHANGES ARE EFFECTIVE JOHN YOUNG AND ANGELA HWANG WILL LEAD PFIZER'S INNOVATIVE MEDICINES BUSINESS.  Full Article

Pfizer's Xeljanz Receives Marketing Authorisation In The European Union For Active Psoriatic Arthritis
Thursday, 28 Jun 2018 

June 28 (Reuters) - Pfizer Inc ::XELJANZ® (TOFACITINIB CITRATE) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR ACTIVE PSORIATIC ARTHRITIS.PFIZER - APPROVAL BASED ON SUBMISSION PACKAGE THAT INCLUDED DATA FROM PHASE 3 ORAL PSORIATIC ARTHRITIS TRIALS CLINICAL DEVELOPMENT PROGRAM IN PSA.  Full Article

Pfizer Declares 34-Cent Third-Quarter 2018 Dividend
Thursday, 28 Jun 2018 

Pfizer Inc ::PFIZER DECLARES 34-CENT THIRD-QUARTER 2018 DIVIDEND.  Full Article

BioMarin Receives $20 Mln In Milestone Payments From Pfizer For Talazoparib
Thursday, 7 Jun 2018 

June 7 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN RECEIVES MILESTONE PAYMENTS FROM PFIZER FOR TALAZOPARIB.BIOMARIN PHARMACEUTICAL INC - COMPANY RECEIVED $20 MILLION IN MILESTONE PAYMENTS FROM PFIZER INC.BIOMARIN PHARMACEUTICAL INC - MILESTONE PAYMENTS ARE PART OF AGREEMENT MADE WITH MEDIVATION, INC. WHEN CO PURCHASED TALAZOPARIB.BIOMARIN PHARMA - MILESTONE PAYMENTS TRIGGERED BY U.S. FDA ACCEPTANCE OF PFIZER'S NEW DRUG APPLICATION (NDA) SUBMISSION FOR TALAZOPARIB.BIOMARIN PHARMA - MILESTONE PAYMENTS ALSO TRIGGERED BY EUROPEAN MEDICINES AGENCY ACCEPTANCE OF PFIZER'S SUBMISSION OF MAA FOR TALAZOPARIB.  Full Article

U.S. FDA And European Medicines Agency Accept Regulatory Submissions For Review Of Talazoparib For Metastatic Breast Cancer Patients With An Inherited BRCA Mutation
Thursday, 7 Jun 2018 

June 7 (Reuters) - Pfizer Inc ::U.S. FDA AND EUROPEAN MEDICINES AGENCY ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF TALAZOPARIB FOR METASTATIC BREAST CANCER PATIENTS WITH AN INHERITED BRCA MUTATION.PFIZER INC - U.S. NEW DRUG APPLICATION GRANTED FDA PRIORITY REVIEW.PFIZER INC - SUBMISSIONS BASED ON DATA FROM EMBRACA, LARGEST PHASE 3 TRIAL PERFORMED TO DATE OF A PARP INHIBITOR IN BRCA-MUTATED MBC.PFIZER INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR A DECISION BY FDA IS IN DECEMBER 2018.  Full Article

Pfizer's Xalkori Receives FDA Breakthrough Therapy Designation In Two New Indications
Tuesday, 29 May 2018 

May 29 (Reuters) - Pfizer Inc ::PFIZER’S XALKORI® (CRIZOTINIB) RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION IN TWO NEW INDICATIONS.PFIZER- FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR XALKORI FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ALCL THAT IS ALK-POSITIVE.  Full Article

ACCC Unsuccessful In Appeal Against Pfizer
Friday, 25 May 2018 

May 25 (Reuters) - Australian Competition and Consumer Commission::FULL COURT OF THE FEDERAL COURT OF AUSTRALIA DISMISSED APPEAL BY ACCC AGAINST EARLIER JUDGMENT IN RELATION TO PFIZER AUSTRALIA PTY LTD.  Full Article

FDA Grants Breakthrough Therapy Designation For Pfizer's Tafamidis
Wednesday, 23 May 2018 

May 23 (Reuters) - Pfizer Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR TAFAMIDIS FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY.PFIZER INC - DECISION IS SUPPORTED BY TOPLINE RESULTS FROM TAFAMIDIS PHASE 3 TRANSTHYRETIN CARDIOMYOPATHY (ATTR-ACT) STUDY.  Full Article

Photo

Pfizer separates consumer health unit in business rejig

Pfizer Inc announced plans on Wednesday to reorganize into three units, separating its consumer healthcare business that the U.S. drugmaker has been trying to sell since last year. | Video